Figure 5
Figure 5. ZAP-70 expression in CD38+ and CD38− cells. PBMCs from 20 elderly healthy donors and 95 patients with CLL were incubated with mAbs to CD5, CD38, CD19, ZAP-70, or appropriate isotype control mAbs. CD19+CD5+ cells exhibiting a ZAP-70 staining in excess of the isotype control mAbs were considered ZAP-70+. (A) Significant differences in percentage of CD5+CD19+ cells expressing ZAP-70 (P < .001; Mann-Whitney test). These data were further analyzed to determine differences in expression of ZAP-70 between the CD38− and CD38+ populations in healthy controls. Horizontal line indicates average of values in corresponding group. (B) and in patients with CLL (C). Significant differences exist between ZAP-70 expression within CD38− and CD38+ subsets from healthy donors and patients with CLL (P < .001; Kruskal-Wallis test).

ZAP-70 expression in CD38+ and CD38 cells. PBMCs from 20 elderly healthy donors and 95 patients with CLL were incubated with mAbs to CD5, CD38, CD19, ZAP-70, or appropriate isotype control mAbs. CD19+CD5+ cells exhibiting a ZAP-70 staining in excess of the isotype control mAbs were considered ZAP-70+. (A) Significant differences in percentage of CD5+CD19+ cells expressing ZAP-70 (P < .001; Mann-Whitney test). These data were further analyzed to determine differences in expression of ZAP-70 between the CD38 and CD38+ populations in healthy controls. Horizontal line indicates average of values in corresponding group. (B) and in patients with CLL (C). Significant differences exist between ZAP-70 expression within CD38 and CD38+ subsets from healthy donors and patients with CLL (P < .001; Kruskal-Wallis test).

Close Modal

or Create an Account

Close Modal
Close Modal